Haematologia , Vol. 30, No. 3, pp. 167 – 176 (2000) Ó VSP 2000. Paper Synthetic cytokines containing interleukin-3 exert potent megakaryopoietic activity N. AHMED, M. A. KHOKHER and H. T. HASSAN ∗ Division of Biomedical Sciences, School of Health Sciences, University of Wolverhampton, United Kingdom Abstract —The shared properties of haematopoietic cytokines and their receptors have enabled the genetically engineered construction of several synthetic cytokines with increased haematopoietic ac- tivity and / or more desirable pharmacological characteristics. Thrombocytopenia remains a signifi- cant cause of morbidity in cancer patients undergoing allogeneic or autologous bone marrow / blood stem cell transplantation after myeloablative therapy including total body irradiation. Several in vitro , in vivo and preliminary clinical studies have demonstrated the efficacy of synthetic cytokines con- taining interleukin-3 in accelerating platelet recovery after radiotherapy-induced myelosuppression, enhancing G-CSF-mobilisation of CD34 positive cells for transplantation and increasing the ex-vivo expansion of myeloid and megakaryocytic progenitor cells. More randomised controlled clinical tri- als are needed to study the efficacy of the pre-transplant platelet mobilisation and the acceleration of the post-transplant platelet recovery. This also applies to cohort in vitro studies for expanding the production of CD41 + megakaryocytes from human bone marrow,
Haematologia – Brill
Published: Jan 1, 2000
Keywords: interleukin; ex-vivo expansion; haematopoiesis; mobilisation; Cytokine
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera